Preeclampsia Market Report and Forecast 2024-2032

Preeclampsia Market Outlook

The preeclampsia market size is expected to grow at a CAGR of 1.8% during the forecast period of 2024-2032, driven by the increasing incidence of pregnancies, along with growing hypertension prevalence across major markets.

Preeclampsia Market Overview

Preeclampsia is a pregnancy complication wherein the mother may have high blood pressure, and elevated protein levels in the urine indicating kidney damage or organ damage. It is one of the most documented gestational complications, affecting around 2-15% of all pregnant women. In 2023, the worldwide incidence of the condition is around 7 million. It is the main cause of 17% maternal deaths and 15% premature births.

The preeclampsia market demand is primarily driven by the increasing incidence of gestational and chronic hypertension in women. It begins after 20 weeks of pregnancy. Symptoms may include decreased levels of platelets in the blood, increased levels of liver enzymes, changes in vision and severe headaches among others. If left untreated, it may lead to fatal complications for the foetus as well as the mother. Consequently, there has been a high focus on developing effective therapeutics as well as diagnostics to alleviate the risks and morbidities associated with the disease.

Intensive Research Activities to Drive the Preeclampsia Market Growth

In September 2023, researchers at Brown University and Western University revealed in a study that the cis P-tau protein, which is commonly associated with neurological diseases such as stroke and Alzheimer’s disease, may also be a biomarker for preeclampsia. This indicates the trend of intensive research to develop better and improved treatment alternatives for patients.

Development in Diagnostic Tools to Provide Early and Appropriate Treatment

In May 2023, Thermo Fisher Scientific received the FDA clearance for two assays, designed to assess the risk of developing preeclampsia in pregnant women. The Placental Growth Factor (PlGF) plus and soluble FMS-like tyrosine kinase-1 receptor (sFlt-1) assays can be used with other lab tests and clinical assessments to evaluate if pregnant hospitalised women are at the verge of developing the complication or not. It is run on the BRAHMS KRYPTOR chemistry analyser for 30 minutes and has been validated on basis of its successful examination on more than 700 pregnant women in 18 hospitals. The rising application and installation of such technologies in hospitals and clinics is expected to increase the preeclampsia market share in upcoming years.

Adding to the preexisting research, the scientists from KU Leuven unveiled that a DNA analysis, which may be done alongside NIPT test (used to detect chromosomal abnormalities in the foetus) can help analyse which women are at the higher risk of preeclampsia in the late stages of their pregnancy.

Expediated Drug Development and Growth in Drug Approvals

In August 2023, Comanche Biopharma Corp. received FDA’s Fast Track Designation for their investigational drug called CBP-4888 for the treatment of sFlt1-mediated pre-term preeclampsia. Based on siRNA therapeutic and delivered subcutaneously, the drug is currently under phase 1 clinical rials. This investigational therapy is expected to offer significant advantage over preexisting treatment alternatives for preeclampsia.

The preeclampsia market value is further fuelled by the growing application of antihypertensive drugs for the treatment. Methyldopa is one of the most common drugs used to treat the condition. Hydralazine and Nifedipine are also frequently used. Statins are amongst the common therapies being used for prevention and treatment. Owing to technical advancements and a better understanding of genetics, the treatment market is expected to grow exponentially in the upcoming years.

Preeclampsia Market Segmentation

Market Breakup by Treatment

• Medication to Lower B.P.

• Corticosteroids

• Anticonvulsants Medication

Market Breakup by Disease Type

• Mild Preeclampsia

• Severe Preeclampsia

Market Breakup by End User

• Hospitals

• Clinics

• Others

Market Breakup by Region

• United States

• EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom

• Japan

Preeclampsia Market Regional Analysis

The United States is projected to dominate the preeclampsia market share in the forecast period. The market value can be attributed to imparting significant focus on decreasing neonatal mortality rates due to premature delivery. With a well-equipped healthcare infrastructure, the government along with the key healthcare companies play a critical role in spreading awareness around early diagnosis of the condition. The rising prevalence of telehealth has bolstered market growth as patients adopt such solutions for immediate consultations.

Europe is a major market for preeclampsia treatment, offering innovative treatment options with the help of novel technologies. The presence of various academic institutions and research centers helps with market growth. Moreover, the increasing number of collaborative projects between universities and pharmaceutical companies is also helping the growth.

In Asia Pacific, Japan holds a substantial share of the market value. Yet, India and China, are projected to witness high preeclampsia market growth. This is because the regions are witnessing significantly more pregnancies than others, increasing the disease prevalence rate. In addition, there is a heightened focus on improving the healthcare infrastructure and developing better therapeutic strategies for the patients.

Preeclampsia Market: Competitor Landscape

In March 2023, Northwell Health and Aegis Ventures' company Ascertain revealed their collaboration aimed at using machine learning technologies to predict preeclampsia. The venture is aimed at reducing maternal mortality rates with new age techniques such as artificial intelligence. The proprietary algorithm displayed a 10- to 15-times increase over the current predictive standard detection, making it a promising methodology of analysis in the forthcoming years.

The key features of the preeclampsia market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Thermo Fisher Scientific Inc.

• Baxter

• Bayer AG

• Merck & Co., Inc

• F. Hoffmann-La Roche Ltd

• Siemens Healthcare GmbH

• PerkinElmer Inc

• Sera Prognostics

• DRG Instruments GMBH

• Metabolomic Diagnostics

• Diabetomics, Inc.

• Hitachi Ltd

• Cardinal Health Inc

• BioMerieux SA

• Fujirebio Diagnostics

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report

Preeclampsia Market Report Snapshots

Preeclampsia Market Size

Preeclampsia Regional Analysis

Preeclampsia Treatment Companies